FDA OKs First Adjuvant Drug for Common Lung Cancer FDA OKs First Adjuvant Drug for Common Lung Cancer

Adjuvant osimertinib significantly cut the risk of disease recurrence or death in patients with stage IB-IIIA EGFR-mutated NSCLC in the ADAURA trial.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news